Cumulative New Cases and Deaths

<table>
<thead>
<tr>
<th>Worldwide</th>
<th>ASEAN+3</th>
<th>Plus-3</th>
<th>ASEAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>268,549,864 Cases</td>
<td>16,661,991 Cases</td>
<td>2,343,259 Cases</td>
<td>14,318,732 Cases</td>
</tr>
<tr>
<td>5,287,534 Deaths</td>
<td>323,517 Deaths</td>
<td>27,346 Deaths</td>
<td>296,171 Deaths</td>
</tr>
</tbody>
</table>

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

Recent Developments

Global News

- **South Africa** is preparing to offer booster doses of the Pfizer-BioNTech and Johnson & Johnson (J&J) vaccines. The J&J booster was initially only available for health workers.
- **Australia** will administer Pfizer-BioNTech vaccines to children aged 5 to 11 starting January 10, 2022, at eight-week interval. Suitability of Moderna doses are being studied.
- Cases of the omicron variant has been doubling every three days in the **UK**. Authorities have cautioned that if recent growth rate continues, at least 50 percent of cases in the next 2-4 weeks are likely to be caused by the omicron variant.

Regional News

- **Japan** has confirmed eight more cases of the omicron variant, bringing the total number of omicron infections to 12 to-date. All eight new cases were imported.
- **Singapore** has reported its first locally transmitted case of the omicron variant. **Singapore** will receive AstraZeneca’s COVID-19 antibody cocktail, Evusheld, by year-end. Evusheld offers additional protection, alongside vaccines to high risk individuals.
- **Korea** will further reduce the interval for booster doses from 4-5 months to three, in a bid to stem record-high increases in infections.
- **Indonesia** has cancelled its planned a nationwide year-end holiday-season restrictions following high vaccination coverage and improved testing capacity. Mobility restrictions will vary depending on the situation in each district.

Vaccine News

- The **US** Food and Drug Administration has authorized Pfizer-BioNTech booster shots for 16- and 17-year-olds. New data suggests that boosters likely bolster immune defenses against the new omicron variant.
- **China** has approved two local COVID-19 neutralizing antibody medicine targeted at individuals above 12 years old and adults with mild COVID-19 symptoms. In Phase 3 trials, the drugs showed a reduction in hospitalization and deaths among non-hospitalized clinically vulnerable patients by 78%.
ASEAN+3 and Selected Economies: COVID-19 Cases and Deaths

**ASEAN+3 and Selected Economies: Cumulative Vaccines Administered**

(Per 100 population)

<table>
<thead>
<tr>
<th>Economy</th>
<th>Total Cases ('000)</th>
<th>Cases per 1M Population</th>
<th>New Cases1</th>
<th>New Cases1 since 20202</th>
<th>New Cases per 1M Pop.</th>
<th>New Cases Since 2022</th>
<th>ΔNew Cases</th>
<th>% New Cases</th>
<th>Total Deaths</th>
<th>New Deaths3</th>
<th>Fatality Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td>268,050</td>
<td>618,462</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,287,534</td>
<td>7,480</td>
<td>2.0</td>
</tr>
<tr>
<td>ASEAN+3</td>
<td>16,662</td>
<td>33,897</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>323,517</td>
<td>556</td>
<td>1.9</td>
</tr>
<tr>
<td>Plus-3</td>
<td>2,343</td>
<td>6,764</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27,346</td>
<td>62</td>
<td>1.2</td>
</tr>
<tr>
<td>ASEAN</td>
<td>14,319</td>
<td>27,133</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>256,171</td>
<td>494</td>
<td>2.1</td>
</tr>
</tbody>
</table>

**China**

100  71  75  0  16  0.1  4,636  0  4.7

**Hong Kong, China**

12 1,634 5 1 1 0.0 213 1 1.7

**Japan**

1,728 13,738 113 1 17 0.0 18,367 1 1.1

**Korea**

504 9,674 6,571 126 3,040 1.4 4,130 61 0.8

**Indonesia**

4,259 15,780 223 1 -89 0.0 143,918 10 3.4

**Malaysia**

2,678 80,626 4,920 148 -87 0.2 30,787 38 1.1

**Philippines**

2,836 25,772 360 9 -190 0.0 49,936 169 1.8

**Singapore**

272 47,699 690 121 -505 0.3 779 6 0.3

**Thailand**

2,161 31,769 5,007 74 601 0.2 21,112 38 1.0

**Brunei Darussalam**

15.30 33,927 27 60 -21 0.2 98 1 0.6

**Cambodia**

120.31 7,187 18 1 -4 0.0 2,974 4 2.5

**Lao PDR**

84.50 11,630 1,144 157 -167 1.4 224 5 0.3

**Myanmar**

525.40 9,843 294 6 -154 0.1 19,157 5 3.6

**Vietnam**

1,367.43 14,184 14,449 150 441 1.1 21,186 218 2.0

**Australia**

226 8,686 1,535 59 162 0.7 2,084 7 0.9

**Brazil**

22,177 104,918 8,325 39 -752 0.0 616,457 183 2.8

**France**

7,912 121,742 46,933 722 -1,066 0.6 117,706 116 1.5

**Germany**

6,443 77,646 52,935 636 -4,500 0.6 105,000 347 1.6

**India**

34,666 25,312 7,212 5 -1,408 0.0 474,111 571 1.4

**United Kingdom**

10,722 159,424 56,144 835 12,025 0.5 146,592 187 1.4

**United States**

49,443 149,352 118,160 357 17,431 1.2 791,016 1,189 1.6

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.
1/ Values show the 7-day average.

---

ASEAN+3 and Selected Economies: Vaccination Progress

(Percent of population)

- **Singapore**
- **Brunei**
- **Korea**
- **Malaysia**
- **Philippines**
- **China**
- **Cambodia**
- **Japan**
- **Vietnam**
- **Thailand**
- **Hong Kong**
- **Lao PDR**
- **Indonesia**
- **Myanmar**
- **United Kingdom**
- **United States**
- **Israel**
- **Germany**
- **India**

Source: Our World in Data via Haver Analytics; and AMRO staff calculations.
Note: Percent of fully vaccinated population shows the number of people who received all doses prescribed by the vaccination protocol (e.g. one dose of a single-dose vaccine, or two doses of a two-dose vaccine). The number in the gray box is the percentage of the population that has received at least one vaccine dose.
World: New Cases by Region

(7-day average; thousand cases)

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

ASEAN+3: Daily New Cases

(7-day average)

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.
ASEAN+3 and Selected Economies: Covid Cycle and Healthcare Indicators

**Sources:** Haver Analytics, sourced from John Hopkins University; World Health Organization; and AMRO staff calculations.


### Selected ASEAN+3: Aggregate Non-Residentials Mobility

(Percentage change from baseline; 5-day moving average)

<table>
<thead>
<tr>
<th>Country</th>
<th>2021 Daily new cases (7-day average)</th>
<th>Hospital Beds to Active Cases</th>
<th>Hospital Bed Density (Beds per 1,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aug</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>75</td>
<td>5,765.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Hong Kong, China</td>
<td>5</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Japan</td>
<td>113</td>
<td>6,943.0</td>
<td>13.4</td>
</tr>
<tr>
<td>Korea</td>
<td>6,571</td>
<td>8.2</td>
<td>11.5</td>
</tr>
<tr>
<td>Indonesia</td>
<td>223</td>
<td>51.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Malaysia</td>
<td>4,920</td>
<td>1.0</td>
<td>1.9</td>
</tr>
<tr>
<td>Philippines</td>
<td>360</td>
<td>4.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Singapore</td>
<td>690</td>
<td>1.6</td>
<td>2.4</td>
</tr>
<tr>
<td>Thailand</td>
<td>5,007</td>
<td>2.0</td>
<td>2.1</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>27.1</td>
<td>1.4</td>
<td>2.7</td>
</tr>
<tr>
<td>Cambodia</td>
<td>18</td>
<td>542.3</td>
<td>0.8</td>
</tr>
<tr>
<td>Lao PDR</td>
<td>1,144</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Myanmar</td>
<td>294</td>
<td>9.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Vietnam</td>
<td>14,449</td>
<td>0.9</td>
<td>2.6</td>
</tr>
<tr>
<td>Australia</td>
<td>1,535</td>
<td>2.9</td>
<td>3.8</td>
</tr>
<tr>
<td>Brazil</td>
<td>8,325</td>
<td>0.4</td>
<td>2.2</td>
</tr>
<tr>
<td>France</td>
<td>46,933</td>
<td>0.5</td>
<td>6.5</td>
</tr>
<tr>
<td>Germany</td>
<td>52,935</td>
<td>0.6</td>
<td>8.3</td>
</tr>
<tr>
<td>India</td>
<td>7,212</td>
<td>8.8</td>
<td>0.7</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>56,144</td>
<td>0.2</td>
<td>2.6</td>
</tr>
<tr>
<td>United States</td>
<td>118,160</td>
<td>0.4</td>
<td>2.9</td>
</tr>
</tbody>
</table>

### World and Selected ASEAN+3: Weekly Scheduled Flight Seats

(Percent year-over-year)

Sources: Official Aviation Guide; and AMRO staff calculations. Note: Scheduled seat capacity data until November 2020 are on monthly basis, and on weekly basis thereafter.

**Selected ASEAN+3:** Indonesia, Malaysia, the Philippines, Thailand, and Singapore. **CLMV:** Cambodia, Lao PDR, Myanmar, and Vietnam.

Sources: Haver Analytics, sourced from Google COVID-19 Community Mobility reports; and AMRO staff calculations. Note: Baseline refers to the median value of the corresponding day in the period Jan 3–Feb 6, 2020. “Non-residentials” refer to the aggregated mobility data for places such as groceries and pharmacies, retail and recreation facilities, transit station and workplaces. **ASEAN-5** = Indonesia, Malaysia, the Philippines, Thailand, and Singapore. **CLMV** = Cambodia, Lao PDR, Myanmar, and Vietnam.